Cargando…

A non-electrolyte haemolysis assay for diagnosis and prognosis of sickle cell disease

Red blood cells (RBCs) from patients with sickle cell disease (SCD) lyse in deoxygenated isosmotic non-electrolyte solutions. Haemolysis has features which suggest that it is linked to activation of the pathway termed P(sickle). This pathway is usually described as a non-specific cationic conductanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Milligan, C, Rees, D C, Ellory, J C, Osei, A, Browning, J A, Hannemann, A, Gibson, J S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Science Inc 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3607166/
https://www.ncbi.nlm.nih.gov/pubmed/23297308
http://dx.doi.org/10.1113/jphysiol.2012.246579
_version_ 1782264086405316608
author Milligan, C
Rees, D C
Ellory, J C
Osei, A
Browning, J A
Hannemann, A
Gibson, J S
author_facet Milligan, C
Rees, D C
Ellory, J C
Osei, A
Browning, J A
Hannemann, A
Gibson, J S
author_sort Milligan, C
collection PubMed
description Red blood cells (RBCs) from patients with sickle cell disease (SCD) lyse in deoxygenated isosmotic non-electrolyte solutions. Haemolysis has features which suggest that it is linked to activation of the pathway termed P(sickle). This pathway is usually described as a non-specific cationic conductance activated by deoxygenation, HbS polymerisation and RBC sickling. The current work addresses the hypothesis that this haemolysis will provide a novel diagnostic and prognostic test for SCD, dependent on the altered properties of the RBC membrane resulting from HbS polymerisation. A simple test represented by this haemolysis assay would be useful especially in less affluent deprived areas of the world where SCD is most prevalent. RBCs from HbSS and most HbSC individuals showed progressive lysis in deoxygenated isosmotic sucrose solution at pH 7.4 to a level greater than that observed with RBCs from HbAS or HbAA individuals. Cytochalasin B prevented haemolysis. Haemolysis was temperature- and pH-dependent. It required near physiological temperatures to occur in deoxygenated sucrose solutions at pH 7.4. At pH 6, haemolysis occurred even in oxygenated samples. Haemolysis was reduced in patients on long-term (>5 months) hydroxyurea treatment. Several manoeuvres which stabilise soluble HbS (aromatic aldehydes o-vanillin or 5-hydroxymethyl, and urea) reduced haemolysis, an effect not due to increased oxygen affinity. Conditions designed to elicit HbS polymerisation in cells from sickle trait patients (deoxygenated hyperosmotic sucrose solutions at pH 6) supported their haemolysis. These findings are consistent with haemolysis requiring HbS polymerisation and support the hypothesis that this may be used as a test for SCD.
format Online
Article
Text
id pubmed-3607166
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Blackwell Science Inc
record_format MEDLINE/PubMed
spelling pubmed-36071662013-08-08 A non-electrolyte haemolysis assay for diagnosis and prognosis of sickle cell disease Milligan, C Rees, D C Ellory, J C Osei, A Browning, J A Hannemann, A Gibson, J S J Physiol Cardiovascular Red blood cells (RBCs) from patients with sickle cell disease (SCD) lyse in deoxygenated isosmotic non-electrolyte solutions. Haemolysis has features which suggest that it is linked to activation of the pathway termed P(sickle). This pathway is usually described as a non-specific cationic conductance activated by deoxygenation, HbS polymerisation and RBC sickling. The current work addresses the hypothesis that this haemolysis will provide a novel diagnostic and prognostic test for SCD, dependent on the altered properties of the RBC membrane resulting from HbS polymerisation. A simple test represented by this haemolysis assay would be useful especially in less affluent deprived areas of the world where SCD is most prevalent. RBCs from HbSS and most HbSC individuals showed progressive lysis in deoxygenated isosmotic sucrose solution at pH 7.4 to a level greater than that observed with RBCs from HbAS or HbAA individuals. Cytochalasin B prevented haemolysis. Haemolysis was temperature- and pH-dependent. It required near physiological temperatures to occur in deoxygenated sucrose solutions at pH 7.4. At pH 6, haemolysis occurred even in oxygenated samples. Haemolysis was reduced in patients on long-term (>5 months) hydroxyurea treatment. Several manoeuvres which stabilise soluble HbS (aromatic aldehydes o-vanillin or 5-hydroxymethyl, and urea) reduced haemolysis, an effect not due to increased oxygen affinity. Conditions designed to elicit HbS polymerisation in cells from sickle trait patients (deoxygenated hyperosmotic sucrose solutions at pH 6) supported their haemolysis. These findings are consistent with haemolysis requiring HbS polymerisation and support the hypothesis that this may be used as a test for SCD. Blackwell Science Inc 2013-03-15 2013-01-07 /pmc/articles/PMC3607166/ /pubmed/23297308 http://dx.doi.org/10.1113/jphysiol.2012.246579 Text en © 2013 The Authors. The Journal of Physiology © 2013 The Physiological Society
spellingShingle Cardiovascular
Milligan, C
Rees, D C
Ellory, J C
Osei, A
Browning, J A
Hannemann, A
Gibson, J S
A non-electrolyte haemolysis assay for diagnosis and prognosis of sickle cell disease
title A non-electrolyte haemolysis assay for diagnosis and prognosis of sickle cell disease
title_full A non-electrolyte haemolysis assay for diagnosis and prognosis of sickle cell disease
title_fullStr A non-electrolyte haemolysis assay for diagnosis and prognosis of sickle cell disease
title_full_unstemmed A non-electrolyte haemolysis assay for diagnosis and prognosis of sickle cell disease
title_short A non-electrolyte haemolysis assay for diagnosis and prognosis of sickle cell disease
title_sort non-electrolyte haemolysis assay for diagnosis and prognosis of sickle cell disease
topic Cardiovascular
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3607166/
https://www.ncbi.nlm.nih.gov/pubmed/23297308
http://dx.doi.org/10.1113/jphysiol.2012.246579
work_keys_str_mv AT milliganc anonelectrolytehaemolysisassayfordiagnosisandprognosisofsicklecelldisease
AT reesdc anonelectrolytehaemolysisassayfordiagnosisandprognosisofsicklecelldisease
AT elloryjc anonelectrolytehaemolysisassayfordiagnosisandprognosisofsicklecelldisease
AT oseia anonelectrolytehaemolysisassayfordiagnosisandprognosisofsicklecelldisease
AT browningja anonelectrolytehaemolysisassayfordiagnosisandprognosisofsicklecelldisease
AT hannemanna anonelectrolytehaemolysisassayfordiagnosisandprognosisofsicklecelldisease
AT gibsonjs anonelectrolytehaemolysisassayfordiagnosisandprognosisofsicklecelldisease
AT milliganc nonelectrolytehaemolysisassayfordiagnosisandprognosisofsicklecelldisease
AT reesdc nonelectrolytehaemolysisassayfordiagnosisandprognosisofsicklecelldisease
AT elloryjc nonelectrolytehaemolysisassayfordiagnosisandprognosisofsicklecelldisease
AT oseia nonelectrolytehaemolysisassayfordiagnosisandprognosisofsicklecelldisease
AT browningja nonelectrolytehaemolysisassayfordiagnosisandprognosisofsicklecelldisease
AT hannemanna nonelectrolytehaemolysisassayfordiagnosisandprognosisofsicklecelldisease
AT gibsonjs nonelectrolytehaemolysisassayfordiagnosisandprognosisofsicklecelldisease